PALISADE BIO, INC. Lessee, Operating Lease, Liability, to be Paid, Year One
PALISADE BIO, INC. (PALI) had Lessee, Operating Lease, Liability, to be Paid, Year One of $94.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2024-11-12
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $94.00K.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $94.00K.
- 2024-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $59.00K.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $136.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2024-09-30 | $94.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $94.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $59.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $136.00K 10-K · filed 2024-03-26 |
| 2023-09-30 | $136.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $136.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $136.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $133.00K 10-K · filed 2023-03-22 |
| 2022-09-30 | $133.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $133.00K 10-Q · filed 2022-08-15 |
| 2021-03-31 | $59.70K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $58.40K 10-K · filed 2021-03-22 |
| 2020-09-30 | $55.90K 10-Q · filed 2020-11-10 |
| 2020-06-30 | $53.80K 10-Q · filed 2020-08-13 |
| 2019-12-31 | $53.50K 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |